CAPR
Income statement / Annual
Last year (2024), Capricor Therapeutics, Inc.'s total revenue was $22.27 M,
a decrease of 11.55% from the previous year.
In 2024, Capricor Therapeutics, Inc.'s net income was -$40.47 M.
See Capricor Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$22.27 M |
$25.18 M |
$2.55 M |
$244,898.00 |
$310,250.00 |
$1.01 M |
$1.67 M |
$1.37 M |
$3.19 M |
$3.78 M |
| Cost of Revenue |
$49.97 M
|
$1.07 M
|
$694,871.00
|
$245,697.00
|
$8.46 M
|
$5.14 M
|
$12.07 M
|
$10.77 M
|
$16.04 M
|
$13.76 M
|
| Gross Profit |
-$27.70 M
|
$24.11 M
|
$1.85 M
|
-$799.00
|
-$8.15 M
|
-$4.14 M
|
-$10.40 M
|
-$9.40 M
|
-$12.85 M
|
-$9.98 M
|
| Gross Profit Ratio |
-1.24
|
0.96
|
0.73
|
-0
|
-26.26
|
-4.12
|
-6.22
|
-6.87
|
-4.03
|
-2.64
|
| Research and Development Expenses |
$49.97 M
|
$36.45 M
|
$21.82 M
|
$13.57 M
|
$8.46 M
|
$5.14 M
|
$12.07 M
|
$10.77 M
|
$16.04 M
|
$13.76 M
|
| General & Administrative Expenses |
$14.87 M
|
$12.37 M
|
$10.43 M
|
$7.61 M
|
$5.54 M
|
$3.60 M
|
$4.93 M
|
$4.76 M
|
$4.93 M
|
$4.37 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.87 M
|
$12.37 M
|
$10.43 M
|
$7.61 M
|
$5.54 M
|
$3.60 M
|
$4.93 M
|
$4.76 M
|
$4.93 M
|
$4.37 M
|
| Other Expenses |
-$49.97 M
|
$0.00
|
$190,582.00
|
$548,207.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.87 M
|
$48.19 M
|
$32.25 M
|
$21.18 M
|
$14.00 M
|
$8.74 M
|
$17.00 M
|
$14.23 M
|
$20.17 M
|
$16.39 M
|
| Cost And Expenses |
$64.84 M
|
$49.26 M
|
$32.25 M
|
$21.18 M
|
$14.00 M
|
$8.74 M
|
$17.00 M
|
$14.23 M
|
$20.17 M
|
$16.39 M
|
| Interest Income |
$0.00
|
$1.73 M
|
$0.00
|
$57,460.00
|
$32,943.00
|
$94,791.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$398,807.00
|
$344,665.00
|
$248,626.00
|
| Depreciation & Amortization |
$1.40 M
|
$1.07 M
|
$694,871.00
|
$245,697.00
|
$143,890.00
|
$171,956.00
|
$157,652.00
|
$144,174.00
|
$134,637.00
|
$110,865.00
|
| EBITDA |
-$41.17 M |
-$23.01 M |
-$29.16 M |
-$20.69 M |
-$13.55 M |
-$7.56 M |
-$15.17 M |
-$12.72 M |
-$18.33 M |
-$12.50 M |
| EBITDA Ratio |
-1.85
|
-0.91
|
-11.44
|
-84.5
|
-43.66
|
-7.52
|
-9.08
|
-9.3
|
-5.75
|
-3.31
|
| Operating Income Ratio |
-1.91
|
-0.96
|
-11.65
|
-85.5
|
-44.13
|
-7.7
|
-9.17
|
-9.41
|
-5.32
|
-3.34
|
| Total Other Income/Expenses Net |
$2.10 M
|
$1.79 M
|
$677,851.00
|
$915,922.00
|
$32,943.00
|
$92,071.00
|
$135,991.00
|
$15.29 M
|
-$1.83 M
|
-$245,513.00
|
| Income Before Tax |
-$40.47 M
|
-$22.29 M
|
-$29.02 M
|
-$20.02 M
|
-$13.66 M
|
-$7.64 M
|
-$15.19 M
|
$2.43 M
|
-$18.81 M
|
-$12.86 M
|
| Income Before Tax Ratio |
-1.82
|
-0.89
|
-11.39
|
-81.76
|
-44.02
|
-7.6
|
-9.09
|
1.78
|
-5.9
|
-3.4
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$677.85
|
-$613,412.00
|
-$176,833.00
|
-$264,027.00
|
$135,991.00
|
$254,633.00
|
$218,946.00
|
$137,761.00
|
| Net Income |
-$40.47 M
|
-$22.29 M
|
-$29.02 M
|
-$19.41 M
|
-$13.48 M
|
-$7.38 M
|
-$15.19 M
|
$2.43 M
|
-$18.81 M
|
-$12.86 M
|
| Net Income Ratio |
-1.82
|
-0.89
|
-11.38
|
-79.25
|
-43.45
|
-7.34
|
-9.09
|
1.78
|
-5.9
|
-3.4
|
| EPS |
-1.15 |
-0.83 |
-1.18 |
-0.84 |
-0.87 |
-1.99 |
-5.17 |
1 |
-10.14 |
-8.09 |
| EPS Diluted |
-1.15 |
-0.83 |
-1.18 |
-0.84 |
-0.87 |
-1.99 |
-5.17 |
0.9 |
-10.14 |
-8.09 |
| Weighted Average Shares Out |
$35.22 M
|
$26.78 M
|
$24.55 M
|
$23.09 M
|
$15.57 M
|
$3.71 M
|
$2.94 M
|
$2.32 M
|
$1.86 M
|
$1.59 M
|
| Weighted Average Shares Out Diluted |
$35.22 M
|
$26.78 M
|
$24.55 M
|
$23.09 M
|
$15.57 M
|
$3.71 M
|
$2.94 M
|
$2.68 M
|
$1.86 M
|
$1.59 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
